IPP Bureau

Zydus Wellness appoints Manish Lal as Head, Global Demand and Supply Organization
Zydus Wellness appoints Manish Lal as Head, Global Demand and Supply Organization

By IPP Bureau - November 02, 2025

With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors

Bristol Myers Squibb posts Q3 2025 revenues $12.2 billion
Bristol Myers Squibb posts Q3 2025 revenues $12.2 billion

By IPP Bureau - November 02, 2025

Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development

BMS’ Cobenfy sees steady start, eyes stronger growth ahead
BMS’ Cobenfy sees steady start, eyes stronger growth ahead

By IPP Bureau - October 31, 2025

Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter

Merck’s Capvaxive shows strong momentum amid industry vaccine decline
Merck’s Capvaxive shows strong momentum amid industry vaccine decline

By IPP Bureau - October 31, 2025

Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks
FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

By IPP Bureau - October 31, 2025

Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success
Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success

By IPP Bureau - October 31, 2025

ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia

FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis
FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis

By IPP Bureau - October 31, 2025

FDA issues warning letter to Philips over manufacturing and quality system deficiencies
FDA issues warning letter to Philips over manufacturing and quality system deficiencies

By IPP Bureau - October 31, 2025

The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days

AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials
AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials

By IPP Bureau - October 31, 2025

Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy
GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

By IPP Bureau - October 31, 2025

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio

Lilly’s Omvoh shows rapid and lasting relief from bowel urgency in ulcerative colitis patients
Lilly’s Omvoh shows rapid and lasting relief from bowel urgency in ulcerative colitis patients

By IPP Bureau - October 31, 2025

India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat
India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat

By IPP Bureau - October 31, 2025

The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million

FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics
FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics

By IPP Bureau - October 31, 2025

The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories

EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours
EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours

By IPP Bureau - October 31, 2025

Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1

Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness
Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness

By IPP Bureau - October 31, 2025

Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their

Latest Stories

Interviews

Packaging